Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following two offers if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
JOIN THE CLUB
Canadian Insider Ad-Free
$49/ year*
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
GO AD-FREE

* Price is subject to applicable taxes. Money back guarantee: For bona fide Ad-Free or Canadian Insider Club subscribers, if you downgrade to Basic or cancel with-in 10 days of first subscribing, we will refund your payment upon request. Immediately after downgrading or cancelling, using the same email that is associated with your account, request a refund via our Contact Us form at the bottom of the page. We will only consider one refund request per household or organization. We cannot accommodate refund requests where an account holder has not provided verifiable address and billing information.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aurinia Pharmaceuticals Inc. (T:AUP)

Business Focus: Bio Therapeutic Drugs

Log in or join to add this stock to your watch list.
May 17, 2019 04:02 pm ET
Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT (9:30am ET) in New York, NY.
May 14, 2019 04:02 pm ET
Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the first quarter ended March 31, 2019 and provided an update on recent operational highlights. Amounts, unless specified otherwise, are expressed in U.S. dollars.
May 10, 2019 07:00 am ET
Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis
In recognition of Lupus Awareness Month and World Lupus Day, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (the “Company”) a late clinical-stage biopharmaceutical company with ongoing research in lupus nephritis (“LN”), today recognized World Lupus Day and Lupus Awareness Month with the launch of awareness and educational initiatives to support people with LN and Systemic Lupus Erythematosus (“SLE”):
May 09, 2019 04:05 pm ET
Aurinia Pharmaceuticals to Release First Quarter 2019 Financial Results on May 14, 2019
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that it will release its first quarter 2019 financial results on Tuesday, May 14, 2019, after the market closes. Aurinia’s management team will host a conference call to discuss the company’s financial results and to provide a general business update.
Apr 30, 2019 06:05 am ET
Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it has appointed Dr. Daniel Billen to its Board of Directors. Dr. Billen’s appointment is effective April 29, 2019 concurrent with the previously announced appointment of Mr. Peter Greenleaf as Chief Executive Officer and elevation of Dr. George Milne to Chairman of the Board.
Apr 24, 2019 04:05 pm ET
Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that members of the management team will present a corporate overview at the 2019 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 30, 2019 at 8:30am PT (11:30am ET) in Toronto, Ontario.
Apr 11, 2019 04:30 pm ET
Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr. Peter Greenleaf as Chief Executive Officer and as a Director on the Aurinia Board. The Company also announced the elevation of George M. Milne, Jr., Ph.D. to Chairman of the Board of Directors. Dr. Richard M. Glickman, who previously announced his plans to retire on November 6, 2018, will step down from his role as Chairman and CEO conc
Mar 19, 2019 04:02 pm ET
Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Mar 14, 2019 07:00 am ET
Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease
In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage biopharmaceutical company with research ongoing in two kidney diseases, Lupus Nephritis (LN) and Focal Segmental Glomerulosclerosis (FSGS), today announced a host of activities, including an initiative with The National Kidney Foundation (NKF), designed to raise awareness for kidney disease. To find out more and to get involved in National Kidney Month, Aurinia invites all to:
Mar 07, 2019 04:05 pm ET
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that it will release its fourth quarter and full year 2018 financial results on Tuesday, March 19, 2019, after the market closes. Aurinia’s management team will host a conference call to discuss the company’s financial results for the fourth quarter and full year 2018 and to provide a general business update.
Feb 27, 2019 06:30 am ET
Aurinia Closes At-The-Market Facility
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30, 2018, in relation to at-the-market (“ATM”) offerings of common shares in the capital of the Company, the Company has completed the sale of 4,608,409 common shares at a weighted average price of US$6.55 for aggregate gross proceeds of approximately US$30 million. No further sales will be conducted pursuant to the ATM.
Feb 25, 2019 07:00 am ET
Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/ TSX:AUP) (the “Company” or “Aurinia”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. patent application 15/835,219, entitled “PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS”. The allowed claims broadly cover the novel voclosporin dosing protocol adhered to and required in both the previously reported Phase II AURA-LV study and the ongoing Phase
Feb 20, 2019 04:01 pm ET
Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference in NYC on February 27, 2019 at 2:30pm ET.
Jan 22, 2019 07:00 am ET
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2 head-to-head study evaluating the efficacy, safety and tolerability of voclosporin ophthalmic solution (VOS 0.2%) versus Restasis®(cyclosporine ophthalmic emulsion 0.05%) for the treatment of dry eye syndrome (DES). Both drugs were shown to be well-tolerated and there was no statistical difference between VOS and Restasis® for the primary endpoint as b
Jan 21, 2019 04:49 pm ET
Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it will report results before the opening of trading and hold a webcast and conference call to discuss the results of its Phase 2, double-masked, head-to-head study of VOS 0.2% versus Restasis® (cyclosporine ophthalmic emulsion 0.05%) to evaluate the efficacy, safety and tolerability at four weeks in subjects with dry eye syndrome (DES).
Dec 19, 2018 08:00 am ET
Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 10, 2019 at 10:00am PST, 1pm EST.
Nov 30, 2018 05:18 pm ET
Aurinia Establishes at-the-Market Facility
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced that it has entered into an Open Market Sale Agreement (the “Sale Agreement”) with Jefferies LLC (“Jefferies”) pursuant to which the Company may from time to time sell, through at-the-market (“ATM”) offerings with Jefferies acting as sales agent or directly to Jefferies acting as principal, such common shares in the capital of the Company (“Common Shares”) as would have an aggregate offering price of up to U
Nov 09, 2018 07:00 am ET
Aurinia to Participate in November Investor Conferences
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.
Nov 08, 2018 04:02 pm ET
Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the third quarter ended September 30, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Oct 25, 2018 07:00 am ET
Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH) (TSX:AUP) today announced that it will release its third quarter 2018 financial results on Thursday, November 8, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the company’s third quarter 2018 financial results and provide a general business update.
Sep 25, 2018 04:01 pm ET
Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has completed enrollment for the AURORA Phase 3 trial ahead of schedule. The target enrollment of 324 patients was surpassed due to high patient demand with 358 lupus nephritis (LN) patients randomized in sites across 27 countries.
Sep 19, 2018 04:01 pm ET
Aurinia to Participate in Upcoming Investor Conferences
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will present a company overview at two upcoming investor conferences.
Aug 28, 2018 07:00 am ET
Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.
Aug 09, 2018 04:02 pm ET
Aurinia Reports Second Quarter Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the second quarter ended June 30, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Jul 30, 2018 04:20 pm ET
Aurinia Pharmaceuticals to Release Second Quarter 2018 Financial Results on August 9, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its second quarter 2018 financial results on Thursday, August 9, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the company’s second quarter 2018 financial results and provide a general business update.
Jul 11, 2018 04:01 pm ET
Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye syndrome (DES).
Jun 25, 2018 07:00 am ET
Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the enrollment of the first patients into the AURORA 2 extension study in lupus nephritis and the initiation of its Phase II trial in focal segmental glomerulosclerosis (FSGS).
Jun 22, 2018 04:30 pm ET
Aurinia Announces Results of Annual General Meeting
Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH / TSX: AUP) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting held on June 21, 2018 (the “Meeting”).
May 10, 2018 04:02 pm ET
Aurinia Reports First Quarter Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the first quarter ended March 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.
May 10, 2018 08:00 am ET
Aurinia Pharmaceuticals Recognizes World Lupus DayTM with Activities Focused on Raising Awareness of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced its support for World Lupus DayTM with activities focused on raising awareness of lupus nephritis (LN). In honor of the day, Aurinia is collaborating with The Mighty,
May 01, 2018 04:23 pm ET
Aurinia Pharmaceuticals to Release First Quarter 2018 Financial Results on May 10, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its first quarter 2018 financial results on Thursday, May 10, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the company’s first quarter 2018 financial results and provide a general business update.
Apr 25, 2018 04:01 pm ET
Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that Celia Economides, Vice President, Corporate and Public Affairs, will present at the Bloom Burton & Co. Healthcare Investor Conference on Thursday, May 3rd at 1:30pm EDT. A webcast will be available and can be accessed via the investor section of the Aurinia website,
Apr 02, 2018 04:01 pm ET
Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Mar 15, 2018 04:02 pm ET
Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the fourth quarter and year ended December 31, 2017. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Feb 28, 2018 04:02 pm ET
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its fourth quarter and full year 2017 financial results on Thursday, March 15, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the company’s financial results for the fourth quarter and full year 2017 and provide a general business update.
Feb 22, 2018 04:07 pm ET
Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Michael Hayden, CM OBC MB ChB PhD FRCP (C) FRSC to its board of directors. Dr. Hayden was most recently the President of Global R&D and Chief Scientific Officer at Teva.
Feb 20, 2018 04:01 pm ET
Aurinia Named Company of the Year by LifeSciences BC
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced it has received this year’s Company of the Year Award from LifeSciences BC. The 2018 LifeSciences BC award winners will be recognized at this year’s annual dinner presented by FARRIS, held on April 19, 2018 in Vancouver.
Feb 14, 2018 08:00 am ET
Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has launched ALL INTM, an educational program for people living with lupus nephritis (LN). ALL IN is designed to raise awareness for LN and to support members of the LN community.
Feb 08, 2018 08:00 am ET
Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Joseph P. “Jay” Hagan. to its board of directors. Mr. Hagan is currently the President and Chief Executive Officer of Regulus Therapeutics.
Feb 06, 2018 08:00 am ET
Aurinia to Present at Leerink Partners 7th Annual Global Healthcare Conference
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its Chief Executive Officer, Richard M. Glickman and Celia Economides, Vice President, Corporate and Public Affairs, will participate in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare Conference on February 14th at 2:30pm ET. A webcast will be available and can be accessed via the investor section of the Aurinia website,
Jan 04, 2018 04:37 pm ET
Aurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that in order to replace its prior expired base shelf prospectus and corresponding shelf registration statement it has filed a preliminary short form base shelf prospectus (the “Preliminary Shelf Prospectus”) with the securities commissions in each of the provinces of Ontario, Alberta and British Columbia in Canada, and a corresponding shelf registration statement on Form F-10 with the U.S. Securities and Exchange Commission (
Dec 11, 2017 04:02 pm ET
Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) announced today that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:^NBI), which will become effective prior to market open on Monday, December 18, 2017.
Nov 14, 2017 04:00 pm ET
Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the third quarter ended September 30, 2017. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Nov 06, 2017 04:05 pm ET
Aurinia Pharmaceuticals to Release Third Quarter 2017 Financial Results on November 14, 2017
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its third quarter 2017 financial results on Tuesday, November 14, 2017, after the market closes. At 4:30 p.m. Eastern Time Aurinia’s management will host a conference call to discuss the company’s financial results for the third quarter 2017 and provide a general business update.
Oct 20, 2017 08:00 am ET
Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia) today announced plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD). Additionally, Aurinia announced plans to evaluate its proprietary nanomicellar voclosporin ophthalmic solution (VOS) for the treatment of keratoconjunctivitis sicca or dry eye syndrome (DES). The advancement of these new indications, in addition to lupus nephritis (LN), represents an expansion of the company’s strategy, pipeline and
Oct 12, 2017 07:00 am ET
Aurinia Receives National Corporate Visionary Award from the Lupus Foundation of America
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced it has received this year’s National Corporate Visionary Award from the Lupus Foundation of America. The award was presented to Dr. Richard and Michelle Glickman and to Aurinia for its long-term commitment to advancing treatments for lupus and lupus nephritis. The award was presented yesterday evening during the Foundation’s Annual Evening of Hope Gala in New York City.
Sep 08, 2017 02:15 pm ET
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices
The Annual Review of the S&P/TSX SmallCap Index
Nov 03, 2016 05:07 am ET
IIROC Trade Resumption - AUP
TORONTO, Nov. 3, 2016 /CNW/ - Trading resumes in:
Nov 02, 2016 01:56 pm ET
IIROC Trading Halt - AUP
TORONTO, Nov. 2, 2016 /CNW/ - The following issues have been halted by IIROC:
Sep 30, 2016 05:01 am ET
IIROC Trade Resumption - AUP
TORONTO, Sept. 30, 2016 /CNW/ - Trading resumes in:
Sep 29, 2016 01:45 pm ET
IIROC Trading Halt - AUP (all issues)
TORONTO, Sept. 29, 2016 /CNW/ - The following issues have been halted by IIROC: